Outside the Lab: Interview With Dr. Greg Stock
In episode one of Outside the Lab, show host Michael Choi interviews Dr. Gregory Stock, CEO of Signum Biosciences. Dr. Stock provides insight into Signum’s business strategy, which is to first focus on the cosmoceutical market and reinvest short term cash flow towards the more lucrative, yet more costly pharmaceutical applications of its discoveries.
Outside the Lab explores the business side of the life sciences industry. We interview CEOs, Venture Capitalists, Consultants and other industry professionals on the dynamic and ever changing lifesciences landscape.
If you know someone who would make an interesting guest on an upcoming show, feel free to contact us.
About Signum Biosciences
Signum Biosciences is a private biotechnology company dedicated to acquiring and developing effective, innovative, economical medicines to prevent and treat diseases of aging. Through research on protein networks that control biological systems, we are developing therapeutic candidates for Alzheimer’s , Parkinson’s, arthritis, cancer, cardiovascular disease and a variety of skin conditions.
All cellular activity is coordinated by cellular communication networks, so when these networks go awry, disease results. In cancer, cells mutate and their growth becomes unregulated. In Alzheimer’s, imbalanced expression of a secreted protein in the brain brings inflammatory responses that lead to memory loss and neuronal cell death. In vascular disease, damage to the vascular endothelium generates inflammation that causes atherosclerotic plaques. In skin, neutrophils aggregate in localized areas and cause damage. Each disease develops from progressively more serious imbalances in regulatory and signal transduction processes.
We have developed a strategy to modulate signal transduction networks globally instead of through specifically targeted receptors and other components. This approach is feasible because cellular networks have their own built-in global regulatory mechanisms that can be tuned to modulate the activities of all components at once with minimal deleterious effects.
More global approaches to regulating human biochemical networks are gaining traction for the treatment of disease, and the cutting-edge biochemistry embodied in our proprietary assays offers an efficient new platform for drug discovery in multi-billion dollar disease markets. Our approach will speed the development and commercialization of innovative new drugs and allow us to spin off validated, well-characterized skin care products during the process.
Discussion
No comments for “Outside the Lab: Interview With Dr. Greg Stock”
Post a comment